183 related articles for article (PubMed ID: 18657104)
21. Long-term Cost-effectiveness of Two GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus in the Italian Setting: Liraglutide Versus Lixisenatide.
Hunt B; Kragh N; McConnachie CC; Valentine WJ; Rossi MC; Montagnoli R
Clin Ther; 2017 Jul; 39(7):1347-1359. PubMed ID: 28625506
[TBL] [Abstract][Full Text] [Related]
22. Lifetime health consequences and cost-effectiveness of rosiglitazone in combination with metformin for the treatment of type 2 diabetes in Spain.
Shearer AT; Bagust A; Ampudia-Blasco FJ; Martínez-Lage Alvarez B; Pérez Escolano I; París G
Pharmacoeconomics; 2006; 24 Suppl 1():49-59. PubMed ID: 16800162
[TBL] [Abstract][Full Text] [Related]
23. Self-monitoring of blood glucose (SMBG) for type 2 diabetes patients treated with oral anti-diabetes drugs and with a recent history of monitoring: cost-effectiveness in the US.
Tunis SL; Minshall ME
Curr Med Res Opin; 2010 Jan; 26(1):151-62. PubMed ID: 19919376
[TBL] [Abstract][Full Text] [Related]
24. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA.
Palmer AJ; Valentine WJ; Chen R; Mehin N; Gabriel S; Bregman B; Rodby RA
Nephrol Dial Transplant; 2008 Apr; 23(4):1216-23. PubMed ID: 18359872
[TBL] [Abstract][Full Text] [Related]
25. Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation.
Czoski-Murray C; Warren E; Chilcott J; Beverley C; Psyllaki MA; Cowan J
Health Technol Assess; 2004 Apr; 8(13):iii, ix-x, 1-91. PubMed ID: 15038907
[TBL] [Abstract][Full Text] [Related]
26. A long-term analysis evaluating the cost-effectiveness of biphasic insulin lispro mix 75/25 and mix 50/50 versus long-acting basal insulin analogs in the United States.
Pollock RF; Curtis BH; Valentine WJ
J Med Econ; 2012; 15(4):766-75. PubMed ID: 22413830
[TBL] [Abstract][Full Text] [Related]
27. Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis.
Lee WC; Samyshkin Y; Langer J; Palmer JL
J Med Econ; 2012; 15 Suppl 2():28-37. PubMed ID: 22834986
[TBL] [Abstract][Full Text] [Related]
28. The cost-effectiveness of exenatide once weekly compared with exenatide twice daily and insulin glargine for the treatment of patients with type two diabetes and body mass index ≥30 kg/m(2) in Spain.
Fonseca T; Clegg J; Caputo G; Norrbacka K; Dilla T; Alvarez M
J Med Econ; 2013 Jul; 16(7):926-38. PubMed ID: 23659201
[TBL] [Abstract][Full Text] [Related]
29. What impact would pancreatic beta-cell preservation have on life expectancy, quality-adjusted life expectancy and costs of complications in patients with type 2 diabetes? A projection using the CORE Diabetes Model.
Palmer AJ; Roze S; Valentine WJ; Minshall ME; Lammert M; Oglesby A; Hayes C; Spinas GA
Curr Med Res Opin; 2004 Aug; 20 Suppl 1():S59-66. PubMed ID: 15324517
[TBL] [Abstract][Full Text] [Related]
30. Cost-utility analysis of intensive blood glucose control with metformin versus usual care in overweight type 2 diabetes mellitus patients in Beijing, P.R. China.
Xie X; Vondeling H
Value Health; 2008 Mar; 11 Suppl 1():S23-32. PubMed ID: 18387063
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US.
Lee WC; Conner C; Hammer M
Curr Med Res Opin; 2011 May; 27(5):897-906. PubMed ID: 21348806
[TBL] [Abstract][Full Text] [Related]
32. Therapy conversion to biphasic insulin aspart 30 improves long-term outcomes and reduces the costs of type 2 diabetes in Saudi Arabia.
Ali M; White J; Lee CH; Palmer JL; Smith-Palmer J; Fakhoury W; Valentine WJ
J Med Econ; 2008; 11(4):651-70. PubMed ID: 19450074
[TBL] [Abstract][Full Text] [Related]
33. Cost-Effectiveness of Empagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus at Increased Cardiovascular Risk in Greece.
Gourzoulidis G; Tzanetakos C; Ioannidis I; Tsapas A; Kourlaba G; Papageorgiou G; Maniadakis N
Clin Drug Investig; 2018 May; 38(5):417-426. PubMed ID: 29349708
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of switching patients with type 2 diabetes from insulin glargine to insulin detemir in Chinese setting: a health economic model based on the PREDICTIVE study.
Yang L; Christensen T; Sun F; Chang J
Value Health; 2012; 15(1 Suppl):S56-9. PubMed ID: 22265068
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of insulin aspart versus human soluble insulin in type 2 diabetes in four European countries: subgroup analyses from the PREDICTIVE study.
Palmer JL; Goodall G; Nielsen S; Kotchie RW; Valentine WJ; Palmer AJ; Roze S
Curr Med Res Opin; 2008 May; 24(5):1417-28. PubMed ID: 18400145
[TBL] [Abstract][Full Text] [Related]
36. A cost-effectiveness analysis of continuous subcutaneous insulin injection versus multiple daily injections in type 1 diabetes patients: a third-party US payer perspective.
St Charles M; Lynch P; Graham C; Minshall ME
Value Health; 2009; 12(5):674-86. PubMed ID: 19171006
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of switching to biphasic insulin aspart from human premix insulin in a US setting.
Palmer JL; Knudsen MS; Aagren M; Thomsen TL
J Med Econ; 2010; 13(2):212-20. PubMed ID: 20350145
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of continuous subcutaneous insulin infusion in people with type 2 diabetes in the Netherlands.
Roze S; Duteil E; Smith-Palmer J; de Portu S; Valentine W; de Brouwer BF; Reznik Y; de Valk HW
J Med Econ; 2016 Aug; 19(8):742-9. PubMed ID: 26985982
[TBL] [Abstract][Full Text] [Related]
39. Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis.
Gaebler JA; Soto-Campos G; Alperin P; Cohen M; Blickensderfer A; Wintle M; Maggs D; Hoogwerf B; Han J; Pencek R; Peskin B
Vasc Health Risk Manag; 2012; 8():255-64. PubMed ID: 22566747
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden.
Ericsson Å; Pollock RF; Hunt B; Valentine WJ
J Med Econ; 2013 Dec; 16(12):1442-52. PubMed ID: 24147661
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]